Is this message not displayed correctly?
Please click here for the online version. |
|
Dear Sir or Madam,
In a recent panel discussion at Venture Café Berlin, I had the privilege of engaging with esteemed colleagues Anela Vukoja, Manuel Grossmann, and Thore Buergel, moderated by Rizgar Saltik, on a topic of utmost importance: What can Europe do to remain competitive in the life sciences sector? Here was our consensus: Strengths of the European life sciences ecosystem boasts a solid foundation in life sciences, characterized by world-class research institutions, innovative enterprises, and a collaborative environment. Our continent is an integral part of the global ecosystem, benefiting from cross-border partnerships that foster opportunities. Europe remains a prime location for capital raising and international scaling. Challenges Hindering Europe's Progress
Despite these strengths, several challenges impede our progress: Access to Capital: Unlike the U.S., Europe faces limitations in funding, particularly for late-stage investments. While early-stage funding is accessible, scaling ambitious R&D projects remains challenging. Talent Shortages: Europe struggles to attract and retain top-tier scientific and commercial talent, especially at the executive level. Cities like Berlin benefit from global talent, yet we need more incentives to retain experts. Bureaucracy: Regulatory and administrative hurdles stifle startups and investments. Reducing bureaucracy requires decisive political action to create a more streamlined system that supports growth and innovation. A Fragmented Ecosystem: Europe's innovation landscape is spread across too many regions, diluting resources and impact. We must consolidate efforts and establish central life sciences hubs in key cities like Berlin. Strategic actions for sustained competitiveness
To address these challenges we are started the following activities in Berlin: Political action to streamline regulatory processes. Focus resources on strategic technology and innovation fields rather than spreading them thinly. Enhance funding from both private investors and government initiatives. Encourage collaboration by promoting early idea-sharing and cooperation among startups. Support the development of young scientists and invest in attracting experienced biotech executives. The challenges we face are significant, but the opportunities for a strong, united and innovation driven Europe are even greater. We are eager to broaden and continue this dialogue, working together to fortify Europe's position in the global life sciences industry.
Dr. Kai Uwe Bindseil
Berlin Partner for Business and Technology |
|
New! Life Sciences Report 2024/2025 Our lastest Life Sciences Report for Berlin-Brandenburg offers an impressive overview of the region's dynamic and innovative ecosystem. It highlights six key areas with particularly strong research and translation activities.
Click here for the life sciences directory with over 760 stakeholders in the region.
Download |
|
|
HealthCapital Berlin-Brandenburg: Welcome to the heart of healthcare innovation! The German capital region is one of the world's leading locations for health and innovation. What makes the region especially strong is the unique concentration and networking of science, clinics, and business.
More than 730 biotech, pharma, and medtech companies benefit from the excellent scientific environment, clinical research landscape, and proximity to policymakers and healthcare professionals. These include global players such as Bayer, B. Braun, Berlin-Chemie, Biotronik, Eckert & Ziegler, Pfizer, Sanofi, Takeda and Thermo Fisher, as well as the many small and medium-sized companies in the healthcare sector.
Read more |
|
|
Building a community for bringing advanced and regenerative therapies to the patients Berlin-Brandenburg is an excellent location for advanced and regenerative therapies (such as gene- and cell-based therapies, GCTs or biomaterial-based approaches). A lot is happening in this field here. Last year, for example, the Bayer/Charité “Berlin Center for Gene and Cell Therapies” opened in June and Bayer Co.Lab relaunched its space in November. On January 20th, the CLIC (BIH’s Clinical Incubator) had its first public event as another highlight for infrastructure and community building in the capital region on advanced and personalized therapies. We spoke with Professor Georg Duda, an expert in building advanced and regenerative therapies, and Garima Bhardwaj from the BIH Clinical Incubator, both from the Berlin Institute of Health at Charité, about research and developments in the field of advanced and regenerative therapies.
Read more |
|
|
AI in the Healthcare Sector – The EU AI Act and its potential Impact With the EU AI Act, the European Union adopted the world's first set of regulations for artificial intelligence (AI) in May 2024. These regulations also have an impact on the application of AI in the healthcare sector. This raises questions such as: What challenges and opportunities does this present? And what does this mean, for example, for patient sovereignty and the further development of AI in the healthcare sector? We talked about this with
Prof. Dr. Alexander Alscher, founder and director of Berlin-based e-health software provider Samedi and holder of the professorship for international management at BSP Berlin, and
Dr. Christian Herles, lawyer and general counsel at Samedi, specialized in IT law, data protection law and e-health regulation.
Read more |
|
|
In Portrait | Berlin-Brandenburg Robotics Network There are more than 60 robotics companies in the Berlin region. In addition, numerous research institutions and projects are devoted to the topic. The Berlin-Brandenburg Robotics Network, borne by the Berlin Partner Business Location Center, is an open platform that contributes to organizing exchange between the many players in the sector and connects them to representatives from other segments to promote innovation.
Read more |
|
|
The tip from our relocation experts: Considering relocating your company to a thriving digital health hub? Have a look at our Digital Health Ecosystem Report of Berlin-Brandenburg which showcases the region's stakeholders and technology focus. Learn how cutting-edge innovations, a robust startup culture, and strong interdisciplinary cooperation, among others, make Berlin-Brandenburg an ideal ecosystem to support your business growth and drive healthcare advancements. We are happy to assist you making your company a part of this thriving ecosystem. Contact us!
Flavia Kruse
Berlin Partner for Business and Technology
MedTech | Healthcare | Digital Health 📧
Read more |
|
|
| | DMEA 2025, Berlin 08 April - 10 April 2025 | Berlin
Read more |
|
BIONNALE 2025 14 May 2025 - 15 May 2025 | Berlin
Read more |
|
GITEX Europe 2025 21 May 2025 - 23 May 2025 | Berlin
Read more |
|
BIO International Convention 16 June 2025 - 19 June 2025 | Boston
Read more |
|
| For more events in the life science region Berlin-Brandenburg click here. |
|
EIB provides €35 million to Formo to expand production of cheese alternatives free from animal products The European Investment Bank (EIB) is providing a €35 million loan to German food tech company Formo. This EIB quasi-equity venture debt loan will enable Formo to further develop and scale up its fermentation processes for producing alternatives to dairy and egg-based products. Read more |
|
|
Lindis Blood Care announces successful financing for its Tumor-Cell-Removal medical device, CATUVAB® Lindis Blood Care, a company aiming to set new standards for blood management during cancer surgeries with its medical device CATUVAB®, today announced the successful first closing of a follow-on financing round. The new investment will be used to prepare for the anticipated approval of the medical device (CE Mark) and product launch in Europe. The FDA process for marketing approval in the US is ongoing. The round was led by Brandenburg Kapital, the venture-capital arm of the investment bank of the State of Brandenburg. High-Tech Gründerfonds, existing and new private investors as well as the founders, Dr. Franzpeter Bracht and Dr. Horst Lindhofer, participated in the financing round.
Read more |
|
Aignostics announces results for Pathology Foundation model developed in collaboration with Mayo Clinic Today, Aignostics announced research results for a new pathology foundation model developed in collaboration with Mayo Clinic Digital Pathology. The model, built in two months using 1.2 million diverse slide images from Mayo Clinic and Charité – Universitätsmedizin Berlin, establishes a new state-of-the-art for performance across more than twenty public benchmarks. In addition, the model is computationally efficient, enhancing its usability relative to existing image-based models. High performance and efficiency were enabled by Aignostics' pathologist-curated development approach, which emphasizes the integration of expert medical knowledge throughout the model development process. Read more |
|
|
Newsweek ranking: Charité once again named among the world’s top 10 hospitals |
|
InfectoPharm invests in AudioCure to advance
Read more |
|
ProBioGen expands protein and viral manufacturing to drive continued growth |
|
AI-supported Mammography revolutionizes breast cancer betection: Landmark german study proves Real-World impact |
|
Science and Technology News
|
|
|
A stronghold in the fight against viruses – new bacterial immune system decoded Bacteria are constantly infected by viruses, so-called phages, which use the bacteria as host cells. However, in the course of evolution, bacteria have developed various strategies to protect themselves from these attacks. Many of these bacterial immunity systems have been known for a long time. Prof. Dr Marc Erhardt and
Prof. Dr Philipp Popp, both from the Institute of Biology at Humboldt-Universität zu Berlin, together with colleagues in Denmark and New Zealand and other partners, have now unveiled the structure and function of a novel bacterial defence system against phages. It was discovered in 2018 by an Israeli research group and named after Zorya, a figure in Slavic mythology. The research results have now been published in the renowned scientific journal Nature.
Read more |
|
Nature study: MIS-C traced to reactivation of the Epstein-Barr virus MIS-C is a serious inflammatory shock that affects children. It can occur several weeks after a COVID infection and can be life-threatening. Until now, however, the precise cause of the condition was unknown. Researchers at Charité – Universitätsmedizin Berlin and the German Rheumatology Research Center (DRFZ), an institute of the Leibniz Association, have identified that reactivation of a pre-existing, dormant infection with the Epstein-Barr virus triggers an excessive inflammatory response. The researchers have detailed their findings in an article in Nature.* These insights open the door to new treatment methods, potentially not limited to MIS-C.
Read more |
|
Not all heart inflammation is the same A group of Berlin researchers in collaboration with international scientists have found differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccination, and non-COVID-19 myocarditis. The find paves the way for more personalized therapies, they report in “Nature Cardiovascular Research.”
Read more |
|
Superglue made from the body’s own Mucus
Read more |
|
PanK4 identified as regulator of glucose and lipid Metabolism
Read more |
|
Why deep sleep is helpful for memory |
|
Developing a CRISPR therapy for muscular dystrophy |
|
Inflammatory messenger fuels Alzheimer’s |
|
When blood cancer starts to spread |
|
Technology and Cooperation Offers
|
|
|
Mobile, Modular, Multimodal Biosignal Acquisition M3BA
Read more |
|
For more news from the cluster healthcare industries click here.
|
|
EDITOR | IMPRINT
This newsletter is operated by the cluster healthcare industries Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology
Fasanenstrasse 85 | 10623 Berlin | Germany
Phone: +49 30 46302-463
Email: healthcapital@berlin-partner.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
Editorial: In cooperation with dpa-Custom Content.
Responsible body in terms of German Press Law
Carolin Meltendorf, Press Spokeswoman Berlin Partner for Business and Technology
© 2025 Berlin Partner for Business and Technology |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.
You want to unsubscribe from the newsletter (to: newsletter@newslettercollector.com)? Please click here. |
|
| |
|
